Form 4: Calidi Biotherapeutics Director, Scott Leftwich, Reports Acquisition of 23,783 Shares of Common Stock

Director Scott Leftwich reports acquiring 23,783 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Summary

• On March 29, 2024, Scott Leftwich, a director of Calidi Biotherapeutics, acquired 23,783 shares of common stock.
• This acquisition was a result of a grant of restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• The RSUs vested fully on the grant date, with each RSU representing the right to receive one share of Calidi Biotherapeutics common stock.
• Following the transaction, Leftwich directly owns 493,686 shares of Calidi Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment but suggests confidence.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
• The RSUs fully vested on the grant date, suggesting immediate alignment of the director's interests with those of the shareholders.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates